Abstract 1593P
Background
Adolescent and young adults (AYA) with underlying cancer often experience multiple General Practitioner (GP) consultations before they are referred to a specialist. Certain patient groups may be at higher risk of such events, but evidence is lacking, particularly from Australia. We aimed to examine GP activity prior to cancer diagnosis in an Australian cohort of AYAs and factors associated with multiple GP consultations.
Methods
We conducted an Australian cohort study of patients aged 18–39 years with incident cancer recorded in the Victorian Cancer Registry between 2008-2022 and linkage to the Patron primary care dataset. We calculated the frequency of GP events in the year before cancer diagnosis (GP consultations, prescriptions, blood test and imaging) and the proportion of patients with multiple GP consultations (≥4) in this period. Using multivariable logistic regression models, we examined associations between multiple pre-diagnostic GP consultations and patient characteristics, including age, sex, socioeconomic status, regional or city location, culturally and linguistically diverse background and main spoken language.
Results
1,712 AYAs with cancer were identified: 276 aged 18–25 and 1,436 aged 26–39. AYAs had a mean of 3 GP consults in the six months pre-diagnosis (range 0-46), with 1,035 (60%) AYAs having a GP consultation in this period and 434 AYAs (25%) consulting a GP 4 or more times. AYAs living in regional Australia were more likely to have 4 or more consultations (adjusted odds ratio (AOR) 1.67, 95%CI 1.32-2.10, p<0.001) as were those diagnosed in more recent years, particularly between 2020-2022 (AOR 1.54, 95%CI 1.14-2.07, p=0.005). In AYAs aged 18-25 years, the most deprived patients were more likely to have multiple GP consults (AOR 3.46, 95%CI 1.55-7.72, p=0.002), with no evidence of an association was observed in AYAs aged 26-40.
Conclusions
Our findings identify AYA patient groups at higher risk of multiple GP consultations before cancer diagnosis and at risk of having a prolonged diagnostic journey. These findings could help to inform policy and prioritise early diagnosis interventions focusing on these patient groups.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
University of Melbourne Human Ethics team in the Office of Research Ethics and Integrity.
Funding
Victorian Adolescent & Young Adult Cancer Service, Peter MacCallum Cancer Centre.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
1594P - Cancer mortality in young population and estimated radon areas in Spain
Presenter: Miquel Ferriol-Galmés
Session: Poster session 10
1598P - Xaluritamig, a STEAP1 x CD3 XmAb 2+1 immune therapy, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Initial results from dose expansion cohorts in a phase I study
Presenter: William Kelly
Session: Poster session 10
1600P - Phase II trial of pembrolizumab and lenvatinib in advanced neuroendocrine prostate cancer (NEPC)
Presenter: Ulka Vaishampayan
Session: Poster session 10
1601P - First results from ZZFIRST: A randomized phase II trial of enzalutamide (EZ) with or without talazoparib (TALA) in metastatic hormone-naïve prostate cancer (mHNPC)
Presenter: Joaquin Mateo
Session: Poster session 10
1602P - CBP-1018, Bi-ligand-drug conjugate (Bi-XDC) drug treated for metastatic castration resistant prostate cancer (mCRPC) patients from phase I study results
Presenter: Kaiwen Li
Session: Poster session 10
1603P - Updated safety and efficacy of tazemetostat (TAZ) plus enzalutamide (ENZ) in patients with metastatic castration-resistant prostate cancer (mCRPC)
Presenter: Wassim Abida
Session: Poster session 10
1604P - PSMA-targeted radioligand therapy (RLT) with 131I-LNTH-1095 (1095) plus enzalutamide (enza) vs enza alone in chemotherapy-naïve patients (pts) whose piflufolastat F 18-avid metastatic castration-resistant prostate cancer (mCRPC) progressed on abiraterone (abi): ARROW
Presenter: Evan Yu
Session: Poster session 10
1605P - Opevesostat (MK-5684/ODM-208), an oral CYP11A1 inhibitor, in metastatic castration-resistant prostate cancer (mCRPC): Updated CYPIDES phase II results
Presenter: Karim Fizazi
Session: Poster session 10
1606P - Mature follow up of phase I dose finding trial of pembrolizumab (pembro) with AR inhibitors (ARI) and priming tumour-targeted radiation with anti-PSMA alpha emitter 225Ac-J591
Presenter: Aaron Holmes
Session: Poster session 10